The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer
Lists
Only you see this
Abstract
The outcomes of PD-1 inhibitor with chemotherapy as a novel treatment for stage IIIA NSCLC in the neoadjuvant setting are satisfactory with respect to the high R0 resection rate and low toxicity profile. Prospective comparative and longer follow-up trials are needed to confirm the long-term outcomes of this novel treatment and to reach definitive conclusions.
BibTeX
@article{wang2021safety,
author = {Jiangfeng Wang and Jianqiang Li and Lei Cai and Sheng Chen and Youhua Jiang},
title = {{The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer}},
journal = {Annals},
year = {2021},
doi = {10.21037/atm-21-670},
}Loading related content...